Rheumatoid Arthritis Clinical Trials in New York

Showing 2181-2200 of 4,168 trials

Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

NCT02311920

This phase I trial studies the safety and best dose of ipilimumab, nivolumab, or both in combination with temozolomide in treating patients with newly diagnosed glioblastoma or gliosarcoma. Monoclonal antibodies, such as ipilimumab and nivolumab, may block tumor growth in different ways by targeting certain cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known which combination is a better treatment for glioblastoma or gliosarcoma.

GliosarcomaSupratentorial Glioblastoma

National Cancer Institute (NCI)32 participantsStarted Apr 2015

San Francisco, California, United States • Atlanta, Georgia, United States • Baltimore, Maryland, United States +8 more locations

COMPLETEDNA< 1 mile

Vesalio NeVa VS for Symptomatic Cerebral Vasospasm Following aSAH (The VITAL Study)

NCT03611790

The objective of the study is to assess the safety and probable benefit of the Neva VS device in patients presenting with symptomatic cerebral vasospasm despite maximal medical management following aSAH.

Cerebral Vasospasm

Vesalio30 participantsStarted Dec 2018

Englewood, Colorado, United States • Jacksonville, Florida, United States • Marietta, Georgia, United States +7 more locations

Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

Vesalio NeVa VS for Symptomatic Cerebral Vasospasm Following aSAH (The VITAL Study)

Rheumatoid Arthritis Trials in Other Cities

Trial on Endovascular Aneurysm Management

Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease

The LEADLESS II IDE Study for the Aveir VR Leadless Pacemaker System

18F-Fluorocholine (18F-FCho) to Distinguish Necrosis From Recurrence in Brain Metastases

Trifocal Intraocular Lens (IOL) Aberrometry Outcomes

Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With IOP

Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204)

Investigation of Sulindac (HLX-0201) and Gaboxadol (HLX-0206) in Male Fragile X Syndrome Patients Aged 13-40

A Study of Use of Ella®, an Emergency Contraceptive, Under Simulated OTC Conditions

Efficacy, Tolerability, and Safety of DFN-15

Trial of Ultrasound Guidance for Reduction of Pediatric Forearm Fractures

Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202)

Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)

Accelerated Corneal Collagen Crosslinking for Keratoconus and Ectasia Using Pulse or Continuous UV-A Light

Transepithelial (Epi-on) Corneal Collagen Crosslinking to Treat Keratoconus and Corneal Ectasia

Comparison of Two Group Wellness Interventions for Individuals With Neurologic Conditions and Their Support Persons

Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma

Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis

Other Conditions in New York